Journals / Psychiatry and behavioral sciences (Online) / 2018 / Cilt: 8 - Sayı: 4

Psychotic Depression Induced by Adalimumab in a Patient with Ankylosing Spondylitis: A Case Report

Pages
204–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies would be important in understanding the role of immune system in the pathophysiology of depression, particularly the sub-types such as psychotic depression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tumor Necrosis Factor Alpha antagonists, which are used for the treatment of inflammatory diseases, are considered to be associated with psychiatric diseases.Herein we have reported an adult ankylosing spondylitis case with psychotic depression induced by adalimumab therapy and improved after treatment.
📊
Key Findings & Data:A 57-year-old male patient.
💡
Conclusion & Impact:Further studies would be important in understanding the role of immune system in the pathophysiology of depression, particularly the sub-types such as psychotic depression.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Tumor Necrosis Factor Alpha antagonists, which are used for the treatment of inflammatory diseases, are considered to be associated with psychiatric diseases.Herein we have reported an adult ankylosing spondylitis case with psychotic depression induced by adalimumab therapy and improved after treatment. We aimed both to discuss the relationship between psychiatric disease and inflammatory factor over this case and to make contribution to the literature. A 57-year-old male patient. He had experienced depressive symptoms nearly 5 months ago after 15 days of adalimumab therapy started for ankylosing spondylitis. Meanwhile, the symptoms of the patient, who continued adalimumab therapy once every two weeks, progressed and accompanied by psychotic symptoms such as disorganized speaking and behavior. The patient was admitted to the psychiatry clinic; however, his complaints did not significantly improve with treatment but rapidly regressed after discontinuation of adalimumab therapy. To our knowledge, there is limited data on the mood episodes triggered by adalimumab. In the present case, presence of a connection between symptom onset and the date of starting the medication, as well as rapid symptom regression with discontinuation of the medication, was considered as “potential adverse drug effect” according to the Naranjo Algorithm. This suggests that alteration in proinflammatory processes such as Tumor Necrosis Factor (TNF) might be associated with the onset of mood episodes. Further studies would be important in understanding the role of immune system in the pathophysiology of depression, particularly the sub-types such as psychotic depression.

🔖

Cite This Article

ERBAY, L. G., SARIOĞLU, F. K., DARILMAZ, C., KARTALCI, Ş. (2018). Psychotic Depression Induced by Adalimumab in a Patient with Ankylosing Spondylitis: A Case Report. Psychiatry and behavioral sciences (Online), Cilt: 8 - Sayı: 4, 204–207. https://ajindex.com/articles/302848

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis driven treatments for bipolar depression? Neurotoxicology 2009;30(4):497–521
  2. O’Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004;19(6):397-403
  3. Adler UC, Marques AH, Calil HM. Inflammatory aspects of depression. Inflamm Allergy Drug Targets 2008;7(1):19-23
  4. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. Depression, comorbidities and the TNF alpha system. Eur Psychiatry 2008;23(6):421-9
  5. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J AM Acad Dermatol 2006;55(4):598-606
  6. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J AM Acad Dermatol 2010;62(5):812-8
  7. Ellard R, Ahmed A, Shah R, Bewley A. Suicide and depression in a patient with psoriasis receiving adalimumab: the role of the dermatologist. Clin Exp Dermatol 2014;39(5):624-7
  8. Austin M, Tan YC. Mania associated with infliximab. Aust N Z J Psychiatry 2012;46(7):684–5
  9. Ceïde ME, Rosenberg PB. Brief manic episode after rituximab treatment of limbic encephalitis. J Neuropsychiatry Clin Neurosci. 2011;23(4):E8
  10. Kaufman KR. Etanercept, anticytokines and mania. Int Clin Psychopharmacol 2005;20(4):239–41
  11. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: the Turkish version of Naranjo adverse drug reactions probability scale. Psychiatry Clin Psychopharmacol 2017;27(2): 205–6
  12. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013;144(1-2):16–27
  13. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1355–61
  14. Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BW. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneu